This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

1. Esophageal Cancer - Pipeline Review, Q3 2011
Published:July 2011
No.Of Pages:133
Price:US $ 500
Report Summary
Global Markets Direct’s, 'Esophageal Cancer - Pipeline Review, Q3 2011', provides
an overview of the Esophageal Cancer therapeutic pipeline. This report provides
information on the therapeutic development for Esophageal Cancer, complete with
latest updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Esophageal
Cancer. 'Esophageal Cancer - Pipeline Review, Q3 2011' is built using data and
information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
* A snapshot of the global therapeutic scenario for Esophageal Cancer.
* A review of the Esophageal Cancer products under development by companies
and universities/research institutes based on information derived from company
and industry-specific sources.
* Coverage of products based on various stages of development ranging from
discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
* Coverage of the Esophageal Cancer pipeline on the basis of therapeutic class,
route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description,
mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Browse All Pharmaceuticals Market Research

2. Reasons to buy
* Identify and understand important and diverse types of therapeutics under
development for Esophageal Cancer.
* Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most
promising pipeline.
* Devise corrective measures for pipeline projects by understanding Esophageal
Cancer pipeline depth and focus of Esophageal Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Esophageal Cancer Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Esophageal Cancer 12
Esophageal Cancer Therapeutics under Development by Companies 14
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 27
Comparative Analysis 27
Mid Clinical Stage Products 28
Comparative Analysis 28
Early Clinical Stage Products 29
Comparative Analysis 29
Discovery and Pre-Clinical Stage Products 30
Comparative Analysis 30
Esophageal Cancer Therapeutics - Products under Development by Companies 31
Esophageal Cancer Therapeutics - Products under Investigation by
Universities/Institutes 33
Companies Involved in Esophageal Cancer Therapeutics Development 53
Bristol-Myers Squibb Company 53
F. Hoffmann-La Roche Ltd. 53
Shionogi & Co., Ltd. 54

3. Amgen Inc. 54
Sanofi-Aventis 55
Eli Lilly and Company 55
GlaxoSmithKline plc 56
GenVec, Inc. 56
Micromet, Inc. 57
Aphios Corporation 57
Cell Therapeutics, Inc. 58
MannKind Corporation 58
Celldex Therapeutics, Inc. 59
BTG International Ltd 59
Sareum Holdings plc 60
Supratek Pharma Inc. 60
GANYMED Pharmaceuticals AG 61
Ascenta Therapeutics, Inc. 61
Merrimack Pharmaceuticals, Inc. 62
PharmaMar, S.A. 62
Krankenhaus-GmbH 63
ImmunoFrontier, Inc. 63
Mebiopharm Co., Ltd. 64
Eurofarma 64
Biotech Pharmaceuticals Co., Ltd. 65
Esophageal Cancer - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Route of Administration 68
Assessment by Molecule Type 71
Late Stage Drug Profiles 74
FOLFOX4 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Docetaxel + Active Symptom Control - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Tykerb + Capecitabine + Oxaliplatin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cisplatin + Capecitabine + Radiation Therapy - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 81
Product Description 81
Mechanism of Action 81

4. R&D Progress 81
Cetuximab + Cisplatin + Docetaxel + Radiation Therapy - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 84
Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Epirubicin + Oxaliplatin + Capecitabine + Panitumumab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Herceptin + Xeloda - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
cisplatin + fluorouracil - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
cisplatin + fluorouracil - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
CapeOx + Lapatinib - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Fluorouracil + Cisplatin + Epirubicin Hydrochloride + Radiation Therapy - Drug
Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Cisplatin + Epirubicin + Fluorouracil - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Esomeprazole + Aspirin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 100

5. Product Description 100
Mechanism of Action 100
R&D Progress 100
Lobaplatin + 5-Fluorouracil + Leucovorin - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Paclitaxel + Cisplatin + Tarceva + Radiotherapy - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 104
Paclitaxel + Cisplatin + Radiotherapy - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Iressa - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Fluorouracil + Cisplatin - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Docetaxel + Nedaplatin - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Irinotecan hydrochloride trihydrate + Cisplatin - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Cisplatin + 5-Fluorouracil + Radical radiotherapy - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Cisplatinum + Fluorouracil - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
FOLFOX regimen + cisplatin + fluorouracil + leucovorin calcium + oxaliplatin - Drug
Profile 115
Product Description 115
Mechanism of Action 115

6. R&D Progress 116
Cisplatin + Fluorouracil - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Esomeprazole - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Navelbine + Cisplatin + Radiotherapy - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Trastuzumab + Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 121
Nimotuzumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
FOLFOX 4 + Radiochemotherapy - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Esophageal Cancer Therapeutics - Discontinued Products 125
Esophageal Cancer - Featured News 126
Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO In
American Journal Of Clinical Oncology 126
Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete
Response With Low Rate Of Side Effects In Patients With Advanced Esophageal
Cancer 126
Apr 22, 2010: Genentech Submits Supplemental Application To FDA For Herceptin
In Advanced HER2-Positive Stomach Cancer 127
Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin
In The Treatment Of Oesophagus Carcinoma 128
Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA
Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus
Carcinoma 128
Sep 14, 2009: Celldex Therapeutics Announces Dosing Of First Patient In Phase I/II
Clinical Trial Of CDX-1401 129
Jun 03, 2009: Paclitaxel Poliglumex (OPAXIO) Added To Cisplatin And Radiation
Produces 45% Pathologic Complete Remissions In Patients With Esophageal Cancer
129
Feb 02, 2009: Shionogi announces it has entered into a licensing agreement on
Peptide vaccines for cancer treatment with OncoTherapy Science, Inc. 130
Sep 24, 2008: OPAXIO Phase II Trial In Esophageal Cancer To Be Presented In

7. Proffered Session At The International Society Of Gastrointestinal Oncology Annual
Meeting 130
Jan 24, 2008: Protherics Starts OncoGel Phase IIb Study In Oesophageal Cancer
131
Appendix 132
Methodology 132
Coverage 132
Secondary Research 132
Primary Research 132
Expert Panel Validation 133
Contact Us 133
Disclaimer 133
List of Tables
Number of Products Under Development for Esophageal Cancer, Q3 2011 12
Products under Development for Esophageal Cancer – Comparative Analysis, Q3
2011 13
Number of Products under Development by Companies, Q3 2011 15
Number of Products under Investigation by Universities/Institutes, Q3 2011 17
Number of Products under Investigation by Universities/Institutes, Q3 2011 18
Number of Products under Investigation by Universities/Institutes, Q3 2011 19
Number of Products under Investigation by Universities/Institutes, Q3 2011 20
Number of Products under Investigation by Universities/Institutes, Q3 2011 21
Number of Products under Investigation by Universities/Institutes, Q3 2011 22
Number of Products under Investigation by Universities/Institutes, Q3 2011 23
Number of Products under Investigation by Universities/Institutes, Q3 2011 24
Number of Products under Investigation by Universities/Institutes, Q3 2011 25
Number of Products under Investigation by Universities/Institutes, Q3 2011 26
Comparative Analysis by Late Stage Development, Q3 2011 27
Comparative Analysis by Mid Clinical Stage Development, Q3 2011 28
Comparative Analysis by Early Clinical Stage Development, Q3 2011 29
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q3 2011
30
Products under Development by Companies, Q3 2011 31
Products under Development by Companies, Q3 2011 32
Products under Investigation by Universities/Institutes, Q3 2011 33
Products under Investigation by Universities/Institutes, Q3 2011 34
Products under Investigation by Universities/Institutes, Q3 2011 35
Products under Investigation by Universities/Institutes, Q3 2011 36
Products under Investigation by Universities/Institutes, Q3 2011 37
Products under Investigation by Universities/Institutes, Q3 2011 38
Products under Investigation by Universities/Institutes, Q3 2011 39
Products under Investigation by Universities/Institutes, Q3 2011 40
Products under Investigation by Universities/Institutes, Q3 2011 41
Products under Investigation by Universities/Institutes, Q3 2011 42

8. Products under Investigation by Universities/Institutes, Q3 2011 43
Products under Investigation by Universities/Institutes, Q3 2011 44
Products under Investigation by Universities/Institutes, Q3 2011 45
Products under Investigation by Universities/Institutes, Q3 2011 46
Products under Investigation by Universities/Institutes, Q3 2011 47
Products under Investigation by Universities/Institutes, Q3 2011 48
Products under Investigation by Universities/Institutes, Q3 2011 49
Products under Investigation by Universities/Institutes, Q3 2011 50
Products under Investigation by Universities/Institutes, Q3 2011 51
Products under Investigation by Universities/Institutes, Q3 2011 52
Bristol-Myers Squibb Company, 2011 53
F. Hoffmann-La Roche Ltd., 2011 53
Shionogi & Co., Ltd., 2011 54
Amgen Inc., 2011 54
Sanofi-Aventis, 2011 55
Eli Lilly and Company, 2011 55
GlaxoSmithKline plc, 2011 56
GenVec, Inc., 2011 56
Micromet, Inc., 2011 57
Aphios Corporation, 2011 57
Cell Therapeutics, Inc., 2011 58
MannKind Corporation, 2011 58
Celldex Therapeutics, Inc., 2011 59
BTG International Ltd, 2011 59
Sareum Holdings plc, 2011 60
Supratek Pharma Inc., 2011 60
GANYMED Pharmaceuticals AG, 2011 61
Ascenta Therapeutics, Inc., 2011 61
Merrimack Pharmaceuticals, Inc., 2011 62
PharmaMar, S.A., 2011 62
Krankenhaus-GmbH, 2011 63
ImmunoFrontier, Inc., 2011 63
Mebiopharm Co., Ltd., 2011 64
Eurofarma, 2011 64
Biotech Pharmaceuticals Co., Ltd., 2011 65
Assessment by Monotherapy Products, Q3 2011 66
Assessment by Combination Products 67
Assessment by Stage and Route of Administration, Q3 2011 70
Assessment by Molecule Type, Q3 2011 73
Discontinued Products 125

9. List of Figures
Number of Products under Development for Esophageal Cancer, Q3 2011 12
Products under Development for Esophageal Cancer – Comparative Analysis, Q3
2011 13
Products under Development by Companies, Q3 2011 14
Products under Investigation by Universities/Institutes, Q3 2011 16
Late Stage Products, Q3 2011 27
Mid Clinical Stage Products, Q3 2011 28
Early Clinical Stage Products, Q3 2011 29
Discovery and Pre-Clinical Stage Products, Q3 2011 30
Assessment by Monotherapy Products, Q3 2011 66
Assessment by Combination Products, Q3 2011 67
Assessment by Route of Administration, Q3 2011 68
Assessment by Stage and Route of Administration, Q3 2011 69
Assessment by Molecule Type, Q3 2011 71
Assessment by Stage and Molecule Type, Q3 2011 72
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog